NasdaqGM - Delayed Quote • USD
Carisma Therapeutics, Inc. (CARM)
At close: May 15 at 4:00 PM EDT
After hours: May 15 at 7:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.3 | -0.26 | -1.26 | -1.24 |
| Low Estimate | -0.43 | -0.42 | -1.79 | -2.07 |
| High Estimate | -0.17 | -0.11 | -0.74 | -0.68 |
| Year Ago EPS | -0.49 | -0.53 | -2.59 | -1.26 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 3.92M | 4.3M | 15.52M | 9.6M |
| Low Estimate | 3.4M | 3.4M | 13.6M | -- |
| High Estimate | 5M | 5M | 18.4M | 15.2M |
| Year Ago Sales | 3.56M | 3.83M | 14.92M | 15.52M |
| Sales Growth (year/est) | 10.10% | 12.40% | 4.00% | -38.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.6 | -0.57 | -0.55 | -0.43 |
| EPS Actual | -0.49 | -0.53 | -0.52 | -0.46 |
| Difference | 0.11 | 0.04 | 0.03 | -0.03 |
| Surprise % | 18.30% | 7.00% | 5.50% | -7.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.3 | -0.26 | -1.26 | -1.24 |
| 7 Days Ago | -0.33 | -0.28 | -1.29 | -1.29 |
| 30 Days Ago | -0.33 | -0.28 | -1.29 | -1.29 |
| 60 Days Ago | -0.51 | -0.51 | -2.13 | -1.87 |
| 90 Days Ago | -0.51 | -0.51 | -2.13 | -1.87 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CARM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 38.80% | -- | -- | 8.30% |
| Next Qtr. | 50.90% | -- | -- | 12.40% |
| Current Year | 51.40% | -- | -- | 5.60% |
| Next Year | 1.60% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.13% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Initiated | BTIG: Buy | 4/11/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/29/2023 |
| Initiated | Capital One: Overweight | 10/3/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/6/2023 |
Related Tickers
VOR Vor Biopharma Inc.
1.7400
+3.57%
RNAC Cartesian Therapeutics, Inc.
26.65
+7.68%
IPSC Century Therapeutics, Inc.
3.0900
-1.90%
PRQR ProQR Therapeutics N.V.
1.9100
-3.78%
LPTX Leap Therapeutics, Inc.
2.8000
+1.82%
RPHM Reneo Pharmaceuticals, Inc.
1.6000
-1.23%
NGNE Neurogene Inc.
33.59
+6.47%
ALXO ALX Oncology Holdings Inc.
15.02
-0.99%
FDMT 4D Molecular Therapeutics, Inc.
25.58
-0.66%
ALVR AlloVir, Inc.
0.7500
-2.86%